跳至主要内容
临床试验/CTRI/2021/03/031720
CTRI/2021/03/031720已完成未知

Safety and Efficacy of Bacillus clausii and Bacillus coagulans Spores as Add on to Standard Therapy to Study the Progress of SARS-CoV-2 Infection in Patients with Moderate Symptoms of COVID-19 - A Randomized, Double Blind, Placebo Control, Three Arm Parallel Group Study.

Dr Mehdi Ali Mirza0 个研究点目标入组 56 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
56

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients of either gender, diagnosed to
  • be COVID-19 positive through RTPCR
  • 2.Patients presenting with moderate
  • 3.Patients of age more than 18 years.
  • 4.Willing to comply with study related
  • procedures.

排除标准

  • 1.Known history of hypersensitivity or
  • allergy to probiotics
  • 2.Pregnant or lactating woman
  • 3.Patients with mild and severe infections,
  • critically ill patients.
  • 4.HIV or HBsAg positive

研究者

发起方
Dr Mehdi Ali Mirza

相似试验